Multaq is a newer medication for treating atrial fibrillation. It’s particular benefit is that it does not require a patient to go into the hospital for initiation of the medications, as many other medications in this category do require.

A recent study showed that in patients on Multaq who did not ‘convert’ to normal rhythm, the medication should be stopped as it increased the potential side effect profile of the medication substantially.

This is good information but does not merit patients being ‘afraid’ of Multaq or stopping it. Since all of the heart rhythm medications have had issues over the years, this makes Multaq a ‘me too’ medication for certain subgroups of patients with A fib.

If you have questions, stop in to discuss or call your cardiologist to review your indications for staying on Multaq.